RealMoney.com's MIDDAY UPDATE

October 29, 2001

http://www.realmoney.com

************************ADVERTISEMENT*************************

$7 Trades, 140+ Offices, #1 Broker!
http://ad.2clk.net/eclk;3498695;1729382257000484863;6518453;133148;;3364


**************************************************************

James J. Cramer: A Healthy Selloff

Keep an eye out for some big tech stocks if they slide a little
further.

http://www.thestreet.com/p/rmoney/jamesjcramer/10003137.html
____________________________________
TSC Technical Forum: General Electric Illuminates the Market's Future

Watch where this stock is headed. Plus, charts of Enron, Lucent,
Schlumberger and more.

http://www.thestreet.com/p/rmoney/techforumrm/10003135.html
____________________________________
The Chartist: It's Starting to Look Like May Again

Enough similarities exist right now, so be wary of chasing stocks on
the upside.

http://www.thestreet.com/p/rmoney/chartistrm/10003141.html
____________________________________
The Teleconomist: Calling Home: Telephone Services Look Attractive
Again

Competitive local exchange carriers finally realize that growth is good
in this plain-vanilla area.

http://www.thestreet.com/comment/theteleconomist/10003099.html
____________________________________
Below the Radar: When Pay Cuts Reach the Top

Some companies are cutting salaries of their top brass, but the move
could be only symbolic.

http://www.thestreet.com/funds/belowradar/10003091.html
____________________________________
Tim Arango: Toys R Us Restructuring Still on Track

The company's pre-Sept. 11 plans to remodel its stores are still in
place and could pay off big.

http://www.thestreet.com/stocks/timarango/10003057.html
____________________________________
FaceOff - Glenn Curtis: One Toy Story Not Going to Infinity and Beyond

With other retailers encroaching and a mediocre balance sheet, Toys R
Us will continue to disappoint.

http://www.thestreet.com/markets/faceoffcurtis/10003056.html
____________________________________
Biotech/Pharmaceuticals: FDA Backs Lilly Sepsis Drug

Conditional approval means the drug has cleared a big hurdle.

http://www.thestreet.com/stocks/biotech/10003148.html
______________________________________________________________________
If you would like to be removed from our bulletin mailing list, or
would like to select which of our bulletins you receive, please go to
the following URL:

http://www.thestreet.com/p/upc/bulletin.jhtml

____________________________________________________________________

Copyright Notice

Except for making one printed copy of this or any other materials,
files or documents available from, accessible through or published by
TheStreet.com Inc. for your personal use (or downloading for the same
limited purpose), these may not be reproduced, republished, broadcast
or otherwise distributed without prior written permission of
TheStreet.com Inc.

For bulk reprints of any article, please contact Brad Glouner at
Reprint Management Services, at (717) 399-1900 ext. 130, or via email
at bglouner@rmsreprints.com.
____________________________________________________________________
For general comments, questions or suggestions, please send an email to
feedback@realmoney.com.

For letters about our editorial content intended for publication,
please send an email to letters@realmoney.com. Remember to include your
full name and city.

If you have a question regarding your account, please contact us at
members@realmoney.com.
____________________________________________________________________

For TheStreet.com's privacy policy, please click here:
http://www.thestreet.com/tsc/about/privacy.html.

Email delivery and ad services are provided by DoubleClick's DARTmail.
Click here for important privacy information:
http://www.privacychoices.org/
____________________________________________________________________
Copyright 2000 TheStreet.com, Inc. All rights reserved.